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Background: Testing for COVID-19 with quantitative reverse transcriptase-polymerase chain reaction (RT-
PCR) may result in delayed detection of disease. Antigen detection via lateral flow testing (LFT) is faster and
amenable to population-wide testing strategies. Our study assesses the diagnostic accuracy of LFT compared
to RT-PCR on the same primarycare patients in Austria.
Methods: Patients with mild to moderate flu-like symptoms attending a general practice network in an Aus-
trian district (October 22 to November 30, 2020) received clinical assessment including LFT. All suspected
COVID-19 cases obtained additional RT-PCR and were divided into two groups: Group 1 (true reactive): sus-
pected cases with reactive LFT and positive RT-PCR; and Group 2 (false non-reactive): suspected cases with a
non-reactive LFT but positive RT-PCR.
Findings: Of the 2,562 symptomatic patients, 1,037 were suspected of COVID-19 and 826 (79.7%) patients
tested RT-PCR positive. Among patients with positive RT-PCR, 788/826 tested LFT reactive (Group 1) and 38
(4.6%) non-reactive (Group 2). Overall sensitivity was 95.4% (95%CI: [94%,96.8%]), specificity 89.1% (95%CI:
[86.3%, 91.9%]), positive predictive value 97.3% (95%CI:[95.9%, 98.7%]) and negative predictive value 82.5%
(95%CI:[79.8%, 85.2%]). Reactive LFT and positive RT-PCR were positively correlated (r = 0.968,95CI=
[0.952,0.985] and k ¼ 0:823, 95%CI=[0.773,0.866]). Reactive LFT was negatively correlated with Ct-value
(r = -0.2999,p < 0.001) and pre-test symptom duration (r = -0.1299,p = 0.0043) while Ct-value was positively
correlated with pre-test symptom duration (r = 0.3733),p < 0.001).
Interpretation: We show that LFT is an accurate alternative to RT-PCR testing in primary care. We note the
importance of administering LFT properly, here combined with clinical assessment in symptomatic patients.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)Keywords:
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Non-pharmaceutical interventions (NPIs) that include impos-
ing severe social distancing restrictions (lockdown) on a national
scale, effective implementation of national Test-Trace-Isolate (TTI)
programmes with wide and mandatory use of face coverings,have been the main means of controlling the spread and prevent-
ing onward transmission of SARS-CoV-2 until the recent start of
large-scale vaccination strategies. Effective TTI includes testing of
symptomatic cases, tracing of their contacts and isolating those
that test positive. While initial reports suggests effectiveness of
vaccination in reducing hospitalisations and deaths from COVID-
19 in age-cohorts that have been vaccinated, [1] its impact on
reducing viral transmission is less clear [2]. In the meantime,
when societies start to reopen with viral resurgence under con-
trol, testing interventions complementary to ongoing vaccination
Research in context
Evidence before this study
An effective test strategy is crucial for the detection of SARS-
CoV-2 and lateral flow testing (LFT) may be a quick alternative
to quantitative reverse transcriptase-polymerase chain reaction
(RT-PCR). Evidence for effective symptomatic case detection
with LFT at scale, in primary care and on the same patient
cohort tested with PT-PCR is limited. After literature search, we
found one comparable study that evaluated the accuracy of
antigen testing using a single test device (Panbio COVID-19 Ag
Rapid Test Device, Abbott), performed by staff experienced in
point-of-care testing in nine primary healthcare centres in
Spain.
Added value of this study
We provide evidence that LFT can accurately detect SARS-CoV-
2 infection as an alternative to RT-PCR testing among symp-
tomatic patients in a real-life primary care setting across a large
geographical area. Our results suggest that LFT at the onset of
symptoms and during early COVID-19 (when Ct-value is low)
could be an accurate alternative to RT-PCR testing and a helpful
strategy for curbing COVID-19 resurgences. Noting that in our
study LFT was administered by self-taught clinicians and deliv-
ered at scale in primary care, we allude to the important aspect
that population-wide LFT testing requires accurate administra-
tion of the test and this needs to be part of the planning
strategy.
Implications of all the available evidence
This study has important implications for patients, general
practice and public health, as once countries start easing lock-
downs, early viral detection within community settings with
population-wide testing will be an important part of the exit
strategies alongside continual vaccination roll-out. We show
that combined with immediate self-isolation, case notification
and contact-tracing, population-wide testing with LFT can be
part of an effective prevention and control strategy of the dis-
ease, via interruption of transmission chains. Therefore, our
study supports efforts of population-wide LFT, but we note the
importance of accurate administration of the tests, which in
our case were conducted by self-trained primary care clinicians.
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onward transmission and future COVID-19 resurgence.
Testing is the first and crucial step of an effective TTI and a key in
prevention and control of infectious disease. Reverse transcriptase-
polymerase chain reaction (RT-PCR) is the gold standard for SARS-
CoV-2 detection [3]. However, population-wide testing with RT-PCR
is expensive, incurs a time delay in result return affecting the rates of
contact tracing and adherence to self-isolation [4]. Furthermore,
inclusion of asymptomatic people in population-wide testing has
resulted in high false positive testing rates associated with low RT-
PCR positivity [5]. False positive results may impact on personal lives,
health systems and society [58]. People may unnecessarily self-iso-
late, feel anxious and depressed, and incur financial loss due to
absence from work; hospital appointments may be cancelled, and
lockdown measures hardened and schools closed [5].
Rapid point-of-care antigen testing using lateral flow tests (LFTs)
has been recommended as an alternative testing modality for symp-
tomatic infection and in population-wide testing [3,9,10]. LFTs are
much cheaper and can be produced in large quantities and deliver
results much quicker: on site and in 1530 min without the need for
Please cite this article as: W. Leber et al., Comparing the diagnostic accur
RT-PCR in primary care (REAP-2), EClinicalMedicine (2021), https://doi.ora laboratory. Previous studies have suggested that they may be less
sensitive in detecting infections with low viral load, i.e. during early
or late stage infections or when self-administered [3].
To date no comparative large-scale studies from primary care
exist that compared the outcomes of both LFT and RT-PCR tests on
the same patient cohort. As a number of countries are looking into
using LFT in population-wide testing, comparing the outcomes of LFT
and RT-PCR regimes, and evaluating the accuracy of implementing
LFT in a general clinical setting such as primary care is fundamental
to understanding the plausibility of this strategy. Our study assesses
such diagnostic accuracy of LFT by comparing it to RT-PCR testing on
the same primary care patients during the second COVID-19 wave in
Austria.
General practice, which delivers access to care for large numbers
of people, has been considered an important partner in supporting
an effective TTI system [6]. Point-of-care testing is agreeable to
patients and may improve engagement with their GP and self-man-
agement of their condition [11,12]. Patients report higher confidence
in point-of-care testing if tests are accurate, [13] and if the tests are
administered and results received directly from the GP [14]. Patients
may feel less anxious with a shorter waiting time for the result, [15]
and they may be more likely to engage with care when seeing the
test result on the display screen of the test device [16]. Although
major health system changes may be required to implement point-
of-care testing in primary care, [17] it may improve diagnostic cer-
tainty and facilitate immediate clinical decision making [11]. So far,
to our knowledge, only one study reported LFT among symptomatic
patients in primary care [18]. In this study, LFT testing, when com-
pared to RT-PCR, identified a small cohort of 43/412 (10.4%) people
presenting within the first seven days of symptoms, on which the
specificity and sensitivity were 100%, and 79.6% respectively.
Our study is set within a general practice network in the district of
Liezen, Austria and includes a time period within the second COVID-
19 epidemic wave (October 22 and November 30, 2020) in Austria.
Following a relatively mild first wave of COVID-19 in spring 2020,
Austria has faced a major second wave since September 2020, result-
ing in a nearly eight-fold increase in the number of daily cases com-
pared to the initial outbreak. As of September 14, 2020, 23/46 (50%)
practices, including 14 sentinel practices participating in the Austrian
National Surveillance Network, [19] started offering LFT as a private
service. Following our recent analysis of the early COVID-19 outbreak
in a ski-resort in Austria (REAP-1), [20] on October 22, 2020, Austria
published national guidelines for the implementation of antigen test-
ing combined with clinical assessment in health care settings includ-
ing general practice [21]. As of that day, antigen testing became
available free of charge to symptomatic patients via a service contract
with the Austrian Health Insurance.
Using the data from this general practice network, we aimed to
quantify the diagnostic accuracy of LFT when compared to RT-PCR
testing among the same patients presenting with mild to moderate
flu-like symptoms to a network of general practitioners in the district




A network of 20 independent general practitioners in the district
of Liezen (population 79,652), Austria, between October 22 and
November 30, 2020. Data were available for this time period, and the
lead clinician (OL) had access to all data. The study used anonymised
data for which approval was granted by the Institute for Advanced
Studies Research Ethics Committee, Austria (reference number:
CASE002_2021_HEHP). Oral consent was obtained from all study par-
ticipants.acy of point-of-care lateral flow antigen testing for SARS-CoV-2 with
g/10.1016/j.eclinm.2021.101011
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23 network practices were invited to participate in this prospec-
tive study. As per national guidelines, [21] patients with mild to mod-
erate flu-like illness (including fever, cough, runny nose, sore throat,
earache, diarrhea, general feeling of illness) received same-day
appointment with a GP for clinical assessment including a nasopha-
ryngeal swab for antigen testing. A subgroup of patients with non-
reactive LFT, who presented with signs and symptoms suggesting of
an alternative clinical diagnosis (e. g. glandular fever illness, bacterial
tonsillitis and otitis media), were not suspected of COVID-19 and did
not receive additional RT-PCR testing. This subgroup of patients was
excluded from this study.
The remaining patients with suspected COVID-19 were tested
with RT-PCR and categorised into four groups depending on their RT-
PCR/LFT testing outcome. Patients testing RT-PCR positive were split
into Groups 1 and 2, namely:
Group 1 (true reactive): Suspected COVID-19 cases with a reactive
LFT, who tested RT-PCR positive.
Group 2 (false non-reactive): Suspected COVID-19 cases with a
non-reactive LFT, who tested RT-PCR positive.
Subsets of Groups 1 and 2, for whom full data were available, were
used in the descriptive, correlation and regression analyses. Patients
testing RT-PCR negative were also split into those testing LFT reactive
(false reactive) and LFT non-reactive (true non-reactive). Data from
patients with negative RT-PCR, for whom CT-values were not avail-
able, were excluded from the regression analysis.
Suspected cases in Group 1 (reactive LFT and positive RT-PCR)
were advised to immediately self-isolate and suspected cases in
Group 2 (non-reactive LFT and positive RT-PCR) were advised to self-
isolate till the return of the RT-PCR result (usually within 24 hours
48 hours). All patients received patient information sheets for self-
care and were advised to call the practice or the national health hot-
line in case of clinical deterioration. For contact tracing, both the
practitioners and the laboratories notified the local public health
authority for any reactive LFT, and positive RT-PCR result respec-
tively. People with false reactive LFT were released from self-isolation
following receipt of a negative RT-PCR result, whilst those with non-
reactive LFT continued to self-isolate for 10 days following a positive
RT-PCR [21].
Five different commercial antigen test kits targeting the SARS-
CoV-2 nucleocapsid antigen were used, including the Abbott Panbio
Ag Rapid Test (sensitivity: 91.4%; specificity: 99.8%; https://www.
abbott.co.uk), nal von minden NADAL COVID19-Ag Test (sensitivity:
97.6%; specificity: 99.9%; https://www.nal-vonminden.com), Roche
SARS-CoV Rapid Antigen Test (sensitivity: 96.52%; specificity:
99.68%; https://www.roche.com/), Boson Rapid SARS-CoV-2 Antigen
Test Card (sensitivity: 96.49%; specificity: 99.03%; https://www.
bosonbio.com) and LumiraDX SARS-CoV-2 Antigen Test (sensitivity:
93.8%; specificity: 98.08%; https://www.lumiradx.com). All test kits
meet the World Health organization (WHO) minimum performance
criteria of 80% sensitivity of and 97% specificity [9]. Clinicians
were advised to self-train on nasopharyngeal sampling using a You-
Tube video from Johns Hopkins University (https://youtu.be/
DSrWjVyxEeg) and to follow the manufacturer’s instructions on the
use of test-kits.
RT-PCR testing was performed in three separate laboratories
located in the cities of Vienna, Graz and Salzburg. The RT-PCR testing
in Vienna was performed in scope of the routine surveillance at the
Center for Virology, Medical University of Vienna. All three laborato-
ries used Roche LightCycler (http://www.roche.com; Switzerland),
and Graz additionally used the EURORealTime-SARS-CoV-2 test of
EUROIMMUN (https://www.euroimmun.de/; Germany) according to
the manufacturer’s instructions. RT-PCR was considered positive at
Ct-value of less than 40 as per the manufacturer’s instructions, and
ambiguous results were confirmed using RNA-dependent RNAPlease cite this article as: W. Leber et al., Comparing the diagnostic accur
RT-PCR in primary care (REAP-2), EClinicalMedicine (2021), https://doi.orpolymerase (RdRP) gene detection (Vienna) and a BD MAXTM System
using original SARS-CoV2 reagents of BD (https://www.bd.com/)
(Graz).
2.3. Statistical analysis
Anonymised data on the number of LFT and RT-PCR tests across all
practices were used to inform Groups 1 and 2. We report the number
of cases detected with each test and evaluate the correlation of RT-
PCR positivity and reactive LFT. Additionally, we quantify the diag-
nostic accuracy of LFT, by comparing it to RT-PCR via reported sensi-
tivity (true-reactivity rate), specificity (true-non-reactivity rate) as
well as the false-reactivity value, and the false-non-reactivity value.
Additionally, correlation analysis across the entire dataset compared
the correlation between the outcomes of LFT and RT-PCR testing esti-
mating both the Pearson correlation coefficient (r) and the Cohen’s
kappa coefficient (k) and their 95% Confidence Interval (95%CI). For a
subset of the dataset, data was available across age, sex, pre-test
duration of symptoms (defined as the period between onset of symp-
toms and antigen testing) and Ct-value (as a measure for inverse viral
load) metrics in conjunction with the outcomes of the two tests.
Logistic regression analysis quantified the association between reac-
tive LFT with symptom duration and Ct-value. All analyses were com-
pleted using STATA 15. This study was reported using the Standards
for Reporting of Diagnostic Accuracy Studies (STARD) guidelines [22].
3. Role of the funding source
The funding source did not have any role in study design, data col-
lection, analysis, interpretation, summarizing the data or decision to
submit the manuscript for publication.
4. Results
Twenty of the 23 (87%) network practices participated in the
study. Between October 22 and November 30, 2020, 2562 patients
with mild to moderate flu-like illness were clinically assessed and
tested with LFT across the 20 intervention practices (Fig. 1). 1525
patients, who tested LFT non-reactive and who presented with signs
and symptoms suggesting a different type of infection, were not sus-
pected of having COVID-19 and excluded from this analysis. The
remaining 1037 patients with suspected COVID-19 infection had RT-
PCR test with 826 (79.7%) testing RT-PCR positive and 201 (19.8%)
testing RT-PCR negative (Table 2). For 10 (0.5%) patients RT-PCR
results were not available and these 10 patients were excluded from
further analysis.
Of those with negative RT-PCR, 179/201 tested LFT non-reactive
(true non-reactive) and 22/201 (10.9%) tested reactive (false reactive)
(Table 1), suggesting specificity of 89.1% (95%CI=[86.3%, 91.9%]).
In patients testing RT-PCR positive, 788/826 tested LFT reactive
(true reactive and within Group 1) and 38 (4.6%) tested LFT non-reac-
tive (false non-reactive), suggesting sensitivity of 95.4%, 95%CI=
[94%,96.8%]). Vice versa, in patients with reactive LFT tests, 788/810
tested RT-PCR positive (positive predictive value 97.3%,95% CI=
[95.9%, 98.7%]), while in patients with non-reactive LFT, 179/217
tested RT-PCR negative (negative predictive value 82.5%,95% CI=
[79.8%, 85.2%]) (Table 1).
Overall, for 1027 patients with both LFT and RT-PCR test out-
comes, these were strongly correlated (r = 0.968, 95%CI=
[0.952,0.985], p < 0.001; and k ¼ 0:823, 95%CI=[0.773,0.866]).
Of the 1037 patients with RT-PCR test result, a total of 545
patients were dropped due to missing data on age (N = 344), sex
(N = 344), duration of symptoms (N = 521) and Ct-value (N = 423);
these included 352/826 patients with positive RT-PCR result, who
were dropped from the regression analysis because of missing data
on age, sex, duration of symptoms and Ct-value. Of the remainingacy of point-of-care lateral flow antigen testing for SARS-CoV-2 with
g/10.1016/j.eclinm.2021.101011
Fig. 1. Flow-chart of the study: with the selection process, total numbers of included and excluded patients and details on the size of the groups based on the STARD guidelines[22].
*23/46 practices in the district of Liezen participated in the practice network.
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were LFT non-reactive but RT-PCR positive (Group 2); the remaining
8 patients were LFT reactive but RT-PCR negative and hence had
missing Ct-values. Consequentially, this small set of patients was also
dropped from further analysis.
Descriptive statistics on the 474 patients with age, gender, dura-
tion of symptoms and Ct-values is shown in Table 2. Patients in Group
1 (true reactive) had shorter pre-test duration of symptoms (mean
3.1 days (range=[1,21])) than patients in Group 2 (false non-reactive)
(4.4 days (range=[1,10])); lower Ct-value (mean 23 (range=[11,36])
vs 30 (range=[18,35])); but similar mean age (49 years (range=
[11,83]) vs. 48 years (range=[6,102])). Furthermore, despite a differ-
ence in the data size for Groups 1 and 2, there was a notable differ-
ence in the distributions across these variables between both groups
(Fig. 2).
4.1. Intercorrelation analysis
Reactive LFT was negatively and significantly correlated with Ct-
value (r = 0.2999, p < 0.001) and duration of symptoms
(r = 0.1299, p = 0.0043), but the association was not statistically sig-
nificant with sex (r = 0.0199, r = 0.6628) and with age (r = 0.0099,Table 1
Sensitivity (true-positive), specificity (true-negative), pos
value (NPV), of lateral flow testing (LFT), when compared
(RT-PCR) on data from 1027 patients from a general practic
RT-PCR negative RT-PCR positive
LFT reactive 22 788
LFT non-reactive 179 38
Total tests 201 826
Specificity 89.1% Sensitivity 95.4
Please cite this article as: W. Leber et al., Comparing the diagnostic accur
RT-PCR in primary care (REAP-2), EClinicalMedicine (2021), https://doi.orp = 0.8292). Ct-value was positively correlated with symptoms
(r = 0.3733), p < 0.001), but not with age (r = 0.0307, p = 0.505) or sex
(r = 0.0778, p = 0.0907).
4.2. Logistic regression
Univariate logistic regression analysis suggests that reactive LFT is
strongly associated with Ct-value <30 ((OR = 0.0345, 95%CI=
[0.0134,0.0891], p < 0.001) and duration of symptoms of 13 days
(OR=0.425, 95%CI=[0.235,0.769], p = 0.005).
5. Discussion
Evidence on the performance of SARS-CoV-2 LFT delivered at scale
and compared to RT-PCR on the same primary care cohort is lacking.
This study demonstrates that using LFTs for people presenting with
mild to moderate flu-like symptoms can reliably and accurately
detect SARS-CoV-2 and is comparable to RT-PCR detection. Across a
large network of 20 general practices, RT-PCR positivity rate among
suspected cases was high at 79.7%; overall LFT sensitivity was 95.4%;
and specificity was 89.1%; with high positive predictive (97.3%) and
negative predictive values (82.5%). Both shorter duration anditive predictive value (PPV) and negative predictive
to reverse transcriptase-polymerase chain reaction
e network in Austria.
Total tests
810 Positive Predictive Value 97.3%
217 Negative Predictive Value 82.5%
1027
%
acy of point-of-care lateral flow antigen testing for SARS-CoV-2 with
g/10.1016/j.eclinm.2021.101011
Table 2
Baseline characteristics of the study participants, and LFT and RT-PCR testing results
among the 474 patients for whom we have full data on age, sex, Ct-value and out-
come of both tests. Legend: LFT, lateral flow testing; RT-PCR, reverse transcriptase-
polymerase chain reaction; Ct, cycle threshold value.
Group 1: LFT
reactive (n = 449)
Group 2: LFT non-




<18 15(614) 14(1118) 15(618)
1834 34(1834) 26(2032) 26(1834)
3549 44(3549) 44(3749) 44(3549)
5059 54.5(5059) 54(5059) 54(5059)
6069 64.5(6069) 64(6064) 63(6069)
7079 76(7079) 72(7173) 75(7079)
80 92(80102) 82(8183) 84(80102)
Females (%) 253(56.3%) 13(52%) 266(56.12%)
Pre-test duration of symptoms, mean days (range)
13 2.1(13) 1.92 (13) 2.063(13)
47 4.7(46) 4.80(46) 4.64(46)
>7 8.4(721) 7.88(710) 8.311(721)
Pre-test duration of symptoms, number of patients (%)
13 322(71.6%) 12(48%) 334(70.5%)
47 91(20.3) 5(20%) 96(20.3%)
>7 36(8.0%) 8(32%) 44(9.2%)
Ct-value, mean (range)
<30 21.9(10.929.9) 24.5(1828) 22(10.929.9)
30 32.2(3036) 32.3(3035) 32(3036)
Ct-value, number of patients (%)
<30 423(94.2%) 9(36%) 431(90.9%)
30 26(5.8%) 16(64%) 43(9.1%)
ARTICLE IN PRESS
JID: ECLINM [m5G;July 7, 2021;20:14]
W. Leber et al. / EClinicalMedicine 00 (2021) 101011 5symptoms and lower Ct-value were significantly associated with
reactive LFT. Combined with clinical assessment, LFT enables high
yield and accurate antigen detection of COVID-19 infectivity among
symptomatic patients in primary care.
Our findings are consistent with studies conducted in hospital and
community (drive through and walk-in centers) and primary care
testing sites, linking sensitivity of antigen testing with shorter dura-
tion of symptoms and low Ct-value. In hospital settings, the Founda-
tion for Innovative New Diagnostics (FIND) reported higher
sensitivity with shorter duration of symptoms (7 days) compared to
overall sensitivity for both the Abbott (Germany 80% to Brazil 90.7%
vs. 76.8% to 88.7%) [23] and the Roche (Switzerland 85.6% to GermanyFig. 2. Distributions of age, duration of symptoms and Ct-values in patients who tested LFT r
(Group 2; (d-f)). The x-axis delineates the number of patients; and the y-axes delineate age
(f)).
Please cite this article as: W. Leber et al., Comparing the diagnostic accur
RT-PCR in primary care (REAP-2), EClinicalMedicine (2021), https://doi.or90.8% vs. 85.5 vs. 86.8%) [24] platforms, and sensitivity was highest at
Ct-value 25 for both the Abbott (96.8% vs. 95.8%) and Roche (100%
to 95.9%) systems. Similarly, a study conducted in two community
testing sites also demonstrated higher sensitivity at low Ct-value
<32 compared to overall sensitivity in both Utrecht (Netherlands)
(95.2% vs 72.6%) and Aruba (98% vs. 81%) respectively [25]. A study
conducted under “real-life” conditions among patients presenting
within seven days of symptom onset in primary care demonstrated
100% sensitivity for Ct<25, compared to the overall sensitivity of
79.6% for the Abbott Panbio test kit [18]. In addition, in terms of sen-
sitivity, nasopharyngeal sampling by clinicians may be superior to
supervised self-swabbing. Sensitivity was higher when conducted by
lab scientists (70.2%) or trained health care workers (73%) when com-
pared to self-swabbing by self-trained members of the public (57.5%)
[26]. To rule out infection in a high prevalence setting, high test sensi-
tivity (true positive value) is more important than high specificity
(true negative value) as a highly sensitive test means there are fewer
false negative results and thus fewer cases of infection are missed
[27]. In our study, sensitivity was 95.4% suggesting that LFT could
rule out infection with more than 95% confidence among those 4.9%
of suspected cases who tested LFT non-reactive. Furthermore, 16/25
of suspected cases with false non-reactive LFT (64%) had CT-value
30, suggesting that these cases were likely no longer infectious at
the time of testing.
The specificity (89,1%) in our study is lower than any value of
clinically validated tests (93.1 to 100%) reported to the ECDC [3].
Our low specificity likely reflects real-world performance of LFT
and may represent faulty test kits, incorrect test kit storage [28]
or test handling such as insufficient specimen collection or incor-
rect timing of incubation of the test [10]. In addition, a false non-
reactive LFT might have resulted from a false negative RT-PCR
test result, [29] and false negative test results due to poor sample
quality or improper transport to remote laboratories cannot be
excluded [30,31]. The only comparable study from primary care,
which achieved high specificity (100%), was conducted in nine
primary care centres by nurses with prior experience in point-of-
care testing and one single test kit from Abbott Panbio (personal
communication) [18]. In contrast, in our study five different LFT
test kits were used across a large number of practices, and lack of
coordination in implementing testing and of training for clinicianseactive and RT-PCR positive (Group 1; (a-c)), and LFT non-reactive and RT-PCR positive
in year ((a) and (d)), pre-test duration of symptoms ((b) and (e)), and Ct-value ((c) and
acy of point-of-care lateral flow antigen testing for SARS-CoV-2 with
g/10.1016/j.eclinm.2021.101011
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racy of the test [32].
In line with these studies, the optimal performance of LFT could
occur among symptomatic patients presenting early and receiving
nasopharyngeal swabs from clinical staff in community settings. LFT
of symptomatic patients in primary care should supplement existing
population-wide testing strategies and may assist rapid and accurate
testing in other settings as part of the gradual reopening of schools
and society. However, training and quality assurance of test operators
and co-ordination of services may be required to optimise test out-
comes [32].
Our study has many strengths. It was conducted in a wide geo-
graphical area and across a large network of practices (N = 20),
including 14 (70%) sentinel practices participating in the Austrian
Influenza Surveillance Network [19]. Data were generated using five
different types of antigen testing platforms and across three laborato-
ries located in different parts of Austria, reflecting the realities of
implementing a local service across a wide geographic region. The
practice network was formed in response to our initial study, [20] a
looming second wave, and national recommendation for implemen-
tation of antigen testing in health care settings, including general
practice [21]. Both the lead researcher (WL) and statistician (JPG) are
routinely involved in service evaluations [20,33]. Data were collected
prospectively using a standard clinical questionnaire and the lead cli-
nician (OL) collated and cross-linked data in a single database. Our
protocol recommending self-isolation for all suspected cases (irre-
spective of the LFT result) mitigated both the risk of unnecessary pro-
longed self-isolation among patients with false reactive LFT and the
risk of infection to others from patients with a false non-reactive
result [29].
Our study has some limitations. Practices independently procured
both LFT kits and RT-PCR testing contracts with one university and
two private laboratories preventing the determination of the accu-
racy of individual test systems used. Clinicians were self-taught and
used five different types of test kits across a large number of practi-
ces. Ct-values can vary between laboratories RT-PCR platforms and
may not be directly comparable [34]. Finally, due to the lack of a pri-
mary care patient register in Austria, we were unable to calculate the
rate of LFT testing across the practices.
Importantly, our study is the first study to demonstrate that
point-of-care antigen testing using LFT combined with clinical assess-
ment of symptomatic patients can rapidly and accurately detect
SARS-CoV-2 infection in primary care. Our study has important impli-
cations for patients, general practice and public health. Symptomatic
patients are likely to benefit from both access to testing in a familiar
primary care setting and when they are most infectious, same-day
clinical assessment with immediate notification of test results, and
opportunity for early self-isolation for those testing LFT reactive.
Prompt public health notification of reactive LFT results may also
speed up the process of contact tracing. LFT testing delivered through
a clinical network enables intervention implementation across a
wide geographical area, knowledge exchange between practitioners,
and better integration with laboratory and public health services. As
the vaccination roll out continues and many countries start easing
lockdown, early viral detection within community settings will form
an important adjunct to national TTI strategies. Immune evasion and
emergence of new virus variants may produce future outbreaks.
Given the acceptability for point of care testing among patients, early
viral detection using LFT, followed by immediate case isolation and
effective contact tracing, would assist in detecting outbreaks early,
hence promptly interrupting transmission chains. Since publication
of our first study (REAP-1)[20], and motivated by its results, Austria
has increased its sentinel sites from 91 to 231 general and pediatric
practices including a majority (70%) of practices participating in this
study, indicating that primary care has become an important strate-
gic partner in implementing the national surveillance system. FuturePlease cite this article as: W. Leber et al., Comparing the diagnostic accur
RT-PCR in primary care (REAP-2), EClinicalMedicine (2021), https://doi.orrecommendations for research should include an evaluation of the
impact of REAP-2 on regional RT-PCR positivity rates and modelling
of antigen testing with LFT at scale vs. different levels of lockdown
and vaccination roll-out strategies.
In summary, we show that symptomatic antigen testing for SARS-
CoV-2 with LFT delivered at scale in a general clinical setting such as
primary care as early as onset symptom, and when viral load is high
and Ct-value is low, can rapidly and accurately detect early COVID-19
among patients presenting with flu-like illness and can be a plausible
alternative to RT-PCR. Implementation of LFT should be accompanied
by standardised training for test operators, quality assurance of test-
ing, and coordination of services.
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